WO1989004371A1 - Plantes ameliorees genetiquement pour resister aux maladies - Google Patents

Plantes ameliorees genetiquement pour resister aux maladies Download PDF

Info

Publication number
WO1989004371A1
WO1989004371A1 PCT/US1988/003908 US8803908W WO8904371A1 WO 1989004371 A1 WO1989004371 A1 WO 1989004371A1 US 8803908 W US8803908 W US 8803908W WO 8904371 A1 WO8904371 A1 WO 8904371A1
Authority
WO
WIPO (PCT)
Prior art keywords
plant
gene
plants
plasmid
cecropin
Prior art date
Application number
PCT/US1988/003908
Other languages
English (en)
Inventor
Jesse M. Jaynes
Kenneth S. Derrick
Original Assignee
Louisiana State University Agricultural And Mechan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Louisiana State University Agricultural And Mechan filed Critical Louisiana State University Agricultural And Mechan
Priority to EP89900103A priority Critical patent/EP0675960A1/fr
Publication of WO1989004371A1 publication Critical patent/WO1989004371A1/fr
Priority to KR1019890701236A priority patent/KR890701005A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
    • A01H1/04—Processes of selection involving genotypic or phenotypic markers; Methods of using phenotypic markers for selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C12N15/8251—Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C12N15/8251—Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis
    • C12N15/8253—Methionine or cysteine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C12N15/8251—Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis
    • C12N15/8254—Tryptophan or lysine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8281—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for bacterial resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8282—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for fungal resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8283—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for virus resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)

Definitions

  • the present invention relates to genetically enhanced plants, and particularly to gymnosperms, monocots and dicots genetically altered to express antifungal and antibacterial peptides and/or to express polypeptides which have high proportions of limiting essential amino acids.
  • a conventional plant breeding program requires as much as ten years to develop a new variety. In addition to the initial hybridization step, several years are typically spent replanting successive generations in order to obtain homozygous plants.
  • An alternative to a conventional plant breeding program is anther culturing in which anthers from one plant are used to pollinate the ovaries of another plant.
  • An alternative to hybridization is somaclonal variation. This technique involves the use of vegetative plant parts, such as callus tissue, as explant material.
  • callus that develops from vegetative explants of rice frequently regenerates plants which have genetic characteristics not found in the variety from which the explant was originally obtained.
  • somatic mutants occur at high frequencies, and the percentage of regenerated plants which differ from the starting variety exceeds, for example, 75 percent in rice.
  • This technique is therefore useful for producing genetic variability. Again, however, there are limits to the extent of variation which can be obtained.
  • the tumor-inducing principle was shown to be a bacterial plasmid from the infective organism Agrobacterium tumefaciens.
  • This plasmid has since been characterized in much detail utilizing the currently available techniques of recombinant DNA technology.
  • the bacterium elicits its response by inserting a small fragment of bacterial plasmid into the plant nucleus where it becomes incorporated and functions as a plant gene. This discovery opened the door to using Agrobacterium and its plasmids as vehicles to carry foreign DNA to the plant nucleus.
  • insects and plant pathogens For example, blight and blast are major diseases of rice plants which can decimate a crop. Some plants cannot be cultivated in certain parts of the world because of the presence of diseases in such locations to which the plants are susceptible.
  • the main diseases in potato are bacterial soft rot and bacterial wilt caused by Erwinia carotovora and Pseudomonas solanacearum, respectively. These diseases are primarily responsible for limiting the growth of potatoes in many areas of Asia, Africa, South and Central America.
  • pesticides are becoming increasingly difficult to use in an effective, and yet environmentally acceptable manner. Therefore, it would be desirable to have available for cultivation plants which are resistant to insects and other pathogens.
  • Hyalophora a type of silk moth
  • mRNAs which culminate in the production of about 15 to 20 new proteins.
  • Lysozyme the antibacterial protein found in egg white and human tears
  • cecropins and attacins two other classes of antibacterial peptides, called cecropins and attacins
  • cecropins and attacins have been purified from hyalophora humor.
  • cecropins and attacins two other classes of antibacterial peptides
  • Hultmark et.al describe the bacteriolytic properties of some cecropins against Gram-negative bacteria.
  • the cecropins described in the Hultmark et al patents were not universally effective against all Gram-negative bacteria.
  • the cecropins described therein lysed Serratia marcescens D61108, but not Serratia marcescens D611.
  • cecropins have generally been reported to have no lytic activity towards eucaryotic cells such as insect cells, liver cells and sheep erythrocytes, as reported in the Hultmark patents; International Patent Publication WO/8604356; Andreu et al, Biochemistry, vol. 24, pp. 1683-88 (1985); Boman et al, Developmental and Comparative Immunology, vol. 9, pp. 551-558 (1985); and Steiner et al, Nature, vol. 292, pp. 246-248 (1981).
  • lytic peptides heretofore known include, for example, the sarcotoxins and lepidopterans . Such peptides generally occur naturally in the immune system of Sarcophaga peregrina and the silkworm, lepidopteran, respectively, as reported in Nakajima et al, The Journal of Biological Chemistry, vol. 262, pp. 1665-1669 (1987) and Nakai et al, Chem. Abst. 106:214351w (1987).
  • Polynucleotide molecules expressible in E. coli and having the sequence araB promoter operably linked to a gene which is heterologous to such host are also known.
  • the heterologous gene codes for a biologically active polypeptide.
  • a genetic construct of a first genetic sequence coding for cecropin operably linked to a second genetic sequence coding for a polypeptide which is capable of suppressing the biological effect of the resulting fusion protein towards an otherwise cecropin-sensitive bacterium is also described in International Publication WO86/04356, July 31, 1986.
  • Hultmark et al patents mentioned above also mention that there are no known antibodies to cecropin, indicating a wide acceptability for human and veterinary applications, including one apparently useful application for surface infections because of the high activity against pseudomonas.
  • EPO publication 182,278 (1986) mentions that sarcotoxins may be expected to be effective in pharmaceutical preparations and as foodstuff additives, and that antibacterial activity of sarcotoxin can be recognized in the presence of serum.
  • Shiba, Che ⁇ t. Abstr. 104: 230430K (1985) also mentions preparation of an injection containing 500 mg lepidopteran, 250 mg glucose and injection water to 5 ml.
  • Publication WO86/04356 to include bactericidally active polypeptides from any insect species and analogs, homologs, mutants, isomers and derivatives thereof having bactericidal activity from 1% of the naturally-occurring polypeptides up to 100 times or higher activity of the naturally-occurring cecropin.
  • Other references generally discuss the effects of the ⁇ -helix conformation and the amphiphilic nature of cecropin and other lytic peptides. It is known that lysozyme and attacins also occur in insect homolymph. For example, it is reported in Okada et al, Biochem. J., vol. 229, pp.
  • Protein malnutrition of this type could be alleviated or eliminated by adding supplements to the diet, which supplements contained polypeptides high in these limiting essential amino acids.
  • Such polypeptides would have to be susceptible to digestion by normal human or animal proteases.
  • polypeptides would be manufactured by cloning and expression of synthetic DNA. Synthetic DNA of a desired sequence can now be constructed using modern chemical techniques, and the DNA can then be cloned into various microorganisms using recombinant DNA technology. It is known, for example, that a synthetic DNA which codes for poly(1-aspartyl-1-phenylalanine) can be cloned and expressed in E. coli. Doel et al, Nucleic Acids Research, Vol. 8, No.
  • the present invention involves the genetic transformation of plants, including gymnosperms, dicots and monocots, to express foreign genes to enhance one or more characteristics of the plants, such as disease or pest resistance, and/or nutritional quality.
  • the invention provides a plant having a heterologous gene encoding for an antimicrobial agent.
  • the gene is preferably expressible, and the plant may be, for example, either a gymnosperm, a monocotyledon or a dicotyledon.
  • the antimicrobial agent may be, for example, a lytic peptide such as attacin, lysozyme or cecropin, or an antiviral agent such as micRNA.
  • the invention provides a plant having a heterologous gene encoding for a polypeptide or protein comprising at least 25-60 weight percent of limiting amino acids selected from lysine, tryptophan, methionine, threonine, and isoleucine.
  • the gene is preferably expressible, and the plant may be a monocot or a dicot.
  • the polypeptide is preferably the product of genes constructed by random synthesis of a mixture of codon pairs for the limiting essential amino acids.
  • the protein is designed for stability and digestability, as well as a high proportion of limiting essential amino acids .
  • a plant having at least a first heterologous gene encoding for an antimicrobial agent, and a second heterologous gene encoding for a polypeptide or protein comprising at least 25-60 weight percent of limiting essential amino acids selected from lysine, tryptophan, methionine, threonine, and isoleucine.
  • the plant may be a monocot or a dicot, and the genes are preferably expressible.
  • Another aspect of the invention is the provision of methods for genetically transforming plants with a heterologous gene coding for (a) antimicrobial agents such as, for example, cecropin and micRNA, or (b) polypeptides comprising at least 25-60 weight percent of limiting essential amino acids selected from lysine, tryptophan, methionine, threonine, and isoleucine.
  • One such method includes the steps of incubating plant protoplasts in the presence of a vector containing the gene under conditions effective to induce uptake of the gene by the protoplasts, selecting and cloning the incubated protoplasts expressing the gene, and regenerating a whole plant from the clones to obtain a plant homozygous for expression of the gene.
  • Another such method includes the steps of electroporating plant protoplasts in the presence of a vector containing the gene, selecting and cloning the electroporated protoplasts expressing the gene, and regenerating a whole plant from the clones to obtain a plant homozygous for expression of the gene.
  • a further such method includes the steps of introducing a vector containing the gene into a plant during development of its reproductive structures, harvesting seeds produced by the plant, generating plants from the seeds, and selecting and reproducing the seed-generated plants to obtain a plant homozygous for expression of the gene.
  • a novel lytic peptide having the amino acid sequence ⁇ , ⁇ or ⁇ wherein ⁇ represents the amino acid sequence LXXLLXLLXXLLXL, ⁇ represents the amino acid sequence LLLLLLLLLSLS or the mirror image thereof so that the "SLS" end thereof is near a terminus of the peptide, and X represents K or R.
  • the plant of the present invention has a heterologous gene coding for an antimicrobial polypeptide and/or a polypeptide relatively high in limiting essential amino acids.
  • the term "plant” generally includes trichophyta, and particularly pteropsida such as gymnosperms, monocots and dicots. Representative examples of monocots include rice, wheat, barley, rye, corn, and other grasses, bananas, palms, lilies, orchids, sedges, and the like.
  • Representative dicots include potatoes, carrots, sweet potatoes, willows, oaks, elm, maples, apples, roses, buttercups, petunias, phlox, violets, sunflowers, and the like.
  • the antimicrobial gene is desirable in ornamental plant species as well as species cultivated for food, fiber, wood products, tanning materials, dyes, pigments, gums, resins, latex products, fats, oils, drugs, beverages and the like.
  • the gene for enhanced nutritional quality is desirably expressed in plants cultivated for food, such as, for example, grains, legumes, nuts, vegetables, fruits, spices and the like, but there is generally no advantage to having this gene expressed in non-food plants.
  • the plants should express the heterologous gene, and are preferably homozygous for expression thereof.
  • the gene will be operably linked to a promoter inducible in the cells of the particular plant.
  • the expression should be at a level such that the characteristic desired from the gene is obtained.
  • the expression of the gene for antimicrobial resistance should confer some measurable enhancement of pathogen resistance to the plant relative to the same species without the gene.
  • the expression of the gene for enhanced nutritional quality should result in a plant having a relatively higher content of one or more limiting essential amino acids compared to that of the same species without the gene.
  • Promotors such as CaMV 19s, CaMV 35s and the like are contemplated as being suitable in most plants.
  • antimicrobial genes in the plants of the present invention generally encode for antibacterial and/or antifungal polypeptides, and/or antiviral agents such as micRNA, not normally found in the particular plant species.
  • Suitable antimicrobial polypeptides are, for example, derived from insect hemolymph, such as attacin.
  • a preferred class of antimicrobial polypeptides include the lytic peptides.
  • Exemplary lytic peptides include lysozymes, cecropins, attacins, melittins, magainins, bombinins, xenopsins, caeruleins, the polypeptide from gene 13 of phage P22, S protein from lambda phage, E protein from phage PhiX174, and the like.
  • lytic peptides such as the melittins , bombinins , and magainins are generally relatively high in lytic activity, and are therefore less preferred since host plant cells may be adversely affected thereby.
  • lytic peptide includes any polypeptide which lyses the membrane of a cell in an in vivo or in vitro system in which such activity can be measured.
  • Suitable lytic peptides used in the present invention have lytic activity toward one or more plant pathogens such as fungi and bacteria.
  • Exemplary fungal pathogens include species of Helminthosporium (e.g. late blight), Trichophyton, Colletotricium, Ceratocystis (e.g. Dutch elm disease), Fusarium, Phytophthorax, Rhigoctoria and the like.
  • Representative examples of bacterial pathogens include species of Pseudomonas, Erwinia (e.g. fire blight), Xanthomonas, Clavibacter and the like.
  • Preferred lytic peptides have from about 30 to about 40 amino acids, at least a portion of which are arranged in an amphiphilic ⁇ -helical conformation having a substantially hydrophilic head with a positive charge density, a substantially hydrophobic tail, and a pair of opposed faces along the length of the helical conformation, one such face being predominantly hydrophilic and the other being predominantly hydrophobic.
  • the head of this conformation may be taken as either the amine terminus end or the carboxy terminus end, but is preferably the amine terminus end.
  • Suitable lytic peptides generally include cecropins such as cecropin A, cecropin B, cecropin D, and lepidopteran; sarcotoxins such as sarcotoxin IA, sarcotoxin IB, and sarcotoxin IC; and other polypeptides such as attacin and lysozyme obtainable from the hemolymph of any insect species which have lytic activity against bacteria and fungi similar to that of the cecropins and sarcotoxins.
  • cecropins such as cecropin A, cecropin B, cecropin D, and lepidopteran
  • sarcotoxins such as sarcotoxin IA, sarcotoxin IB, and sarcotoxin IC
  • other polypeptides such as attacin and lysozyme obtainable from the hemolymph of any insect species which have lytic activity against bacteria and fungi similar to that of the cecropins and sarcotoxins.
  • lytic peptides may be obtained as the lytically active portion of larger peptides such as certain phage proteins such as S protein of ⁇ phage, E protein of Phix174 phage and P13 protein of P22 phage; and C9 protein of human complement.
  • classes of lytically active peptides such as, for example, “cecropins,” “attacins” and “phage proteins,” and specific peptides within such classes, are meant to include the lytically active analogues, homologues, fragments, precursors, mutants or isomers thereof unless otherwise indicated by context.
  • those having fewer than about 30 amino acids such as the melittins are generally less preferred in the present invention because of their lack of specificity for bacteria and fungi as indicated by their hemolytic potential, whereas those with more than about 40 amino acids such as attacins and lysozymes may not be sufficiently lytic when used alone to provide a broad spectrum of microbial resistance.
  • those having between about 30 and about 40 amino acids, such as cecropins and sarcotoxins are generally more preferred because of their specificity for lysing pathogens over host cells.
  • Hydrophilic amino acids generally include and generally have the respective relative degree of hydrophobicity (at pH 7.0; kcal/mol) as follows: aspartic acid (D), -7.4; glutamic acid (E) -9.9; asparagine (N), -0.2; glutamine (Q), -0.3; lysine (K), -4.2; arginine (R), -11.2; serine (S), -0.3; and cysteine (C), -2.8.
  • Hydrophobic amino acids generally include and generally have the respective relative degree of hydrophobicity as follows: histidine (H), 0.5; threonine (T), 0.4; tyrosine (Y), 2.3; tryptophan (W) , 3.4; phenylalanine (F), 2.5; leucine (L), 1.8; isoleucine (I), 2.5; methionine (M), 1.3; valine (V), 1.5; and alanine (A), 0.5.
  • Glycine has a relative degree of hydrophobicity of 0 and may be considered to be hydrophilic or hydrophobic.
  • amino acid homology of peptides can be readily determined by contrasting the amino acid sequences thereof as is known in the art.
  • amphiphilic homology of peptides can be determined by contrasting the hydrophilicity and hydrophobicity of the amino acid sequences.
  • the amino acid sequences of some preferred lytic peptides are compared to cecropin B by tabulation and construction of Edmundson helical wheels in the aforementioned application U.S. Serial No. 102,175.
  • Cecropin B is a potent bacteriolytic peptide which occurs naturally and can be obtained from insects as described in the Hultmark et al patents mentioned above, by direct peptide synthesis, or from genetically transformed host cells as described in the aforementioned Publication WO/086/04356. As determined by construction of a helical wheel, fourteen of the sixteen amino acids on the hydrophilic face of cecropin B are hydrophilic, while eleven of the twenty amino acids on the hydrophilic face are hydrophilic, for a total of eleven "imperfections". It is contemplated that the removal or replacement of Gly 23 and Pro 24 would result in a more lytic peptide with only six imperfections in the amphiphilic helical conformation.
  • Cecropin SB-37 is an analogue which was prepared using a peptide synthesizer and is about as lytically active as cecropin B. It has 94% homology therewith in its amino acid sequence and its amphiphilicity.
  • cecropin A which is about as lytically active as cecropin B and SB-37
  • these peptides are generally less lytically active against bacteria than cecropin B.
  • the lytic activity thereof may be improved by removing amino acids from the sequence thereof, for example, Val 19 and Ile 20 from cecropin D or Gly 23 and Pro 24 from lepidopteran or cecropin A.
  • peptide designated herein as "Shiva 1" was prepared using a peptide synthesizer and has the amino acid sequence MPRWRLFRRIDRVGKQIKQGILRAGPAIALVGDARAVG. While this peptide has only a 46% amino acid homology with cecropin B, its amphiphilic homology therewith is 100%. Quite surprisingly, however, Shiva 1 is generally much more lytically active than cecropin B, and it is contemplated that its lytic activity may be further enhanced by removal or replacement of Gly 23 and Pro 24 .
  • a cecropin SB-37 homologue designated herein as "*cecropin SB-37" is identical thereto except for the substitution of glutamic acid in the fourth position (for threonine; corresponding to the second position of cecropin B) and lysine in the eighth position (for leucine; corresponding to the sixth position in cecropinB). Substitutions in these positions may reduce the lytic activity of the cecropin SB-37 against procaryotes by as much as 90% as reported in Andreu et al (1985) mentioned above. Quite surprisingly, however, it has been found that the lytic activity of *cecropin SB-37 against many pathogens is generally comparable to cecropin SB-37.
  • lytic peptides contemplated as being suitable for expresison in the plants of the present invention include polypeptides having the sequence ⁇ , ⁇ , and ⁇ , wherein ⁇ has the amino acid sequence LXXLLXLLXXLLXL, ⁇ has the amino acid sequence LLLLLLLLLSLS or the mirror image thereof so that the "SLS" end thereof is near or at a terminus of the peptide, preferably the amino terminus, and each X independently represents K or R.
  • the following polypeptides are designated herein as indicated: DESIGNATION SEOUENCE X
  • Shiva 3, Shiva 4 and Shiva 7 may be too lytically active to be used in plants at high expression levels, and might need to be employed at relatively low expression levels.
  • all of these Shiva polypeptides are contemplated as having general utility as lytic peptides separate and apart from expression in the plants of this invention, e.g. in inducing lysis of cells in vitro.
  • the amino acid sequences of the foregoing exemplary lytic peptides as well as other lytic peptides contemplated for use in the plant transformants in the present invention are listed in Table I. TABLE I
  • DNA sequences coding for the foregoing peptides can be readily determined and synthesized according to established principles and techniques in the art.
  • antiviral agents inclusive of micRNA or antisense RNA for viruses and viroids replicatable in plants .
  • Exemplary viruses infectious in plants include tobacco mosaic virus , tobacco ringspot virus , potato leaf-roll virus , potato viruses X and Y and the like.
  • Representative examples of viroids replicatable in plants include potato spindle tuber viroid, cadang-cadang viroid, avocado sun blotch viroid, and the like .
  • Antisense RNA, or micRNA as it is sometimes called, generally inhibits or blocks translation of viruses and viroids so that replication thereof in infected plant cells is inhibited or prevented.
  • Such micRNA is preferably complementary to the micRNA (or DNA in the case of RNA viruses) of the virus replication gene, and such complementarity and concomitant hybridization prevents translation or transcription thereof.
  • a single micRNA appears to be sufficient for protection against all known viroids because of a common DNA sequence in their central conserved regions.
  • several micRNA's may be required to block a wide spectrum of viruses.
  • An exemplary genetic sequence for a micRNA complementary to the tobacco mosaic virus is as follows: 5' GATCTCCACGGTTGTGGCCATATAATCATCGTGTTTTTCAA 3'
  • Exemplary contemplated genetic sequences for micRNA's complementary to the African cassava mosaic virus are as follows:
  • ACMV1 5' AGGGGCCAACCGTA 3'
  • ACMC2 5' GCCCCGGTTGGCAT 3'.
  • Viroid antisense RNA's are coded by the following exemplary DNA sequences:
  • PSTV1 5' GATCTAGGGATCCCCGGGGAAACCT 3' PSTV2; 5' GATCTAGGTTTCCCCGGGGATCCCT 3' .
  • a predominant limiting factor in animal and human nutrition is protein quality.
  • Certain proteins, such as egg protein, are considered to be of very high quality because they contain disproportionately high levels of limiting essential amino acids.
  • Limiting essential amino acids are those which are found in very restricted quantities in most proteins, and which, when ingested by an organism, limit the amount of protein which that organism can produce.
  • the five most limiting essential amino acids are lysine, methionine, tryptophan, threonine and isoleucine. Of the total protein in egg, 22.8% consists of these limiting amino acids.
  • the average cereal grain protein (rice, corn, wheat, barley) is composed of about 13% of these five most limiting essential amino acids. The following Tables list these five limiting amino acids in the cereal grains and in roots and tubers. TABLE II
  • lysine is the first limiting amino acid in a cereal and tryptophan is the first limiting amino acid in a root or tuber diet for a human child.
  • tryptophan is the first limiting amino acid in a root or tuber diet for a human child.
  • the other amino acids become limiting depending upon which of these foods is being consumed.
  • the first limiting amino acid would be methionine.
  • the present embodiment provides an ideal polypeptide for use in supplementing the diets of animals and humans to meet their daily limiting essential amino acid requirement.
  • the polypeptide of the present embodiment is particularly suitable for supplementing diets which consist largely of cereals, roots, tubers and legumes.
  • the present invention provides a polypeptide which has elevated levels as compared to proteins known in the art, of lysine, methionine, tryptophan, threonine and isoleucine.
  • the polypeptides of this invention will contain from 25-60 weight percent of these limiting essential amino acids.
  • the polypeptide preferably contains at least two of these limiting essential amino acids, more preferably at least three, and especially four or all five.
  • a protein will be defined as an amino acid chain containing more than 50 amino acids.
  • a polypeptide will be an amino acid chain having less than 50 amino acids.
  • the cloning and expression of synthetic DNA containing repeated selected codons for limiting essential amino acids are used as a means for improving the amino acid profiles of single cell proteins.
  • single cell production of polypeptides composed largely of limiting essential amino acids are used to supplement cereal, root, tuber and/or legume diets and feed grain rations and other foodstuffs.
  • Such supplemented foodstuffs would include any suitable foodstuff, particularly legumes, roots, tubers and cereal grains.
  • the test method used generally involves isolating a plasmid from a microbe such as E. coli.
  • the plasmid may be isolated by any desired procedure, but preferably a cleared lysate procedure is employed.
  • the plasmid is digested with restriction enzyme such as, for example, EcoRI to yield a linear molecule with an interrupted chloramphenicol resistance gene at the 72nd amino acid of the chloramphenicol-acetyl transferase (CAT) protein.
  • restriction enzyme such as, for example, EcoRI
  • Synthesis of the genes may be by random ligation of mixtures of small oligodeoxynucleotides.
  • the products of ligation are heterogenous with respect to molecular weight.
  • a dodecomeric linker which contains the enzyme recognition sequence for the restriction endonuclease such as EcoRI is at a concentration which should yield, upon digestion with EcoRI, fragments of a mean size of about 400 base pairs (bp).
  • Suitable recombinant E. coli. strains are then selected for further characterization and designated. In the process of this invention, the designations given were SP44 and SP47. These designated strains contain nucleotide fragments cleaved by EcoRI of approximately 100 bp and 300 bp, respectively.
  • Polypeptide synthesis is determined by the relative uptake of labeled amino acids by the recombinant E. coli. strains as compared to controls.
  • the polypeptide sequences produced can be derived from the known nucleotide sequences of the DNA.
  • Lactalbumin is a high quality milk protein, and zein is a poor quality major protein in maize. It will be seen from Table IV that proper supplementation of zein with SP44(1) or (2) or SP47(1) or (2), would markedly improve the balance of the five most limiting amino acids.
  • the method of gene synthesis is flexible enough to produce amino acid profiles which would be specifically designed to supplement the material to be enhanced, in this case, maize. It should be pointed out that the insertion of lysine (or arginine) at frequent intervals in these polypeptides, preferably on the average of every fifth to tenth amino acid, will provide numerous sites for proteolytic attack by trypsin.
  • the present embodiment provides polypeptides which contain appropriate amino acids to provide a high quality product and also to be in a form which will be used to supplement foodstuffs having low quality proteins.
  • the polypeptides may be described as being composed largely of the amino acids lysine, methionine, tryptophan, threonine, and isoleucine, which amino acids constitute '25-60 weight percent of the polypeptide.
  • a protein of the present invention has the following amino acid sequence: GDRKKWMDRHPFLHPFLTIPFLKKWMKKWM TIHPFLHPFLTIKKWMKKWMKKWMHPF
  • a smaller polypeptide which has somewhat lower quality than the foregoing large protein has the following amino acid sequence: GTITIHPFLKKWMTIHPFLKKWMTIHPFLP
  • Table V which sets forth the percentage of limiting essential amino acids in a number of food proteins, and compares those percentages with the supplementary polypeptide of this invention.
  • a particularly preferred embodiment is a protein which is relatively more stable due to alternating charges in the amino acid side chains which are adjacent to each other in ⁇ -helical conformations of the protein, and which contains few, and preferably no ⁇ -helix disrupters, such as proline.
  • Such proteins are contemplated as having a greater utility since they would be more stable, i.e., less subject to proteolytic attack by the plant enzymes, and expressible in a wider variety of plants.
  • An exemplary protein with such characteristics, and also with approximately 20 percent of its amino acids being randomly inserted lysine, has the amino acid sequence as follows:
  • DNA sequences coding for the foregoing peptides can also be readily determined and synthesized according to established principles and techniques in the art, e.g. synthesis of the oligonucleotide, or portions thereof followed by ligation.
  • the plants of the present invention may be obtained by any of several methods. Such methods generally include direct gene transfer, chemically-induced gene transfer, electroporation, microinjection, Agrobacterium-mediated gene transfer, and the like. Some methods, such as Agrobacterium-mediated gene transfer, are generally only suitable for certain types of plants, e.g. dicots, while the other methods can generally be used to transform monocots and gymnosperms as well.
  • One method for obtaining the present plants is direct gene transfer in which plant cells are cultured or otherwise grown in the presence of DNA oligonucleotides containing the gene desired to be introduced into the plant.
  • the donor DNA source is typically a plasmid or other suitable vector containing the desired gene.
  • plasmids For convenience, reference is made below to plasmids, with the understanding that other suitable vectors containing the desired gene are also contemplated.
  • Any suitable plant tissue which takes up the plasmid may be treated by direct gene transfer. Such plant tissue includes, for example, reproductive structures at an early stage of development, particularly prior to meiosis, and especially 1-2 weeks pre-meiosis.
  • the pre-meiotic reproductive organs are bathed in plasmid solution, such as, for example, by injecting plasmid solution directly into the plant at or near the reproductive organs.
  • the plants are then self-pollinated, or cross-pollinated with pollen from another plant treated in the same manner.
  • the plasmid solution typically contains about 10-50 ⁇ g DNA in about 0.1-10 ml per floral structure, but more or less than this may be used depending on the size of the particular floral structure.
  • the solvent is typically sterile water, saline, or buffered saline, or a conventional plant medium.
  • the plasmid solution may also contain agents to chemically induce or enhance plasmid uptake, such as, for example, PEG, Ca 2+ or the like.
  • the floral structure is grown to maturity and the seeds are harvested.
  • selection of the transformed plants with the marker gene is made by germination or growth of the plants in a marker-sensitive, or preferably a marker-resistant medium.
  • seeds obtained from plants treated with plasmids having the kanamycin resistance gene can be identified to have taken up the plasmid by germinating the seeds in kanamycin. Plants expressing the kanamycin resistance gene will remain green, whereas those without this marker gene are albino. Presence of the desired gene transcription of mRNA therefrom and expression of the peptide can further be demonstrated by conventional Southern, northern, and western blotting techniques.
  • plant protoplasts are treated to induce uptake of the plasmid.
  • Protoplast preparation is well-known in the art and typically involves digestion of plant cells with cellulase and other enzymes for a sufficient period of time to remove the cell wall. Typically, the protoplasts are separated from the digestion misture by seiving and washing.
  • the protoplasts are then suspended in an appropriate medium, such as, for example, medium F, CC medium, etc., typically at 10 4 - 10 7 cells/ml.
  • an inducer such as polyethylene glycol, Ca 2+ , Sendai virus or the like.
  • the plasmids may be encapsulated in liposomes.
  • the solution of plasmids and protoplasts are then incubated for a suitable period of time, typically about 1 hour at about 25°C. In some instances, it may be desirable to heat shock the mixture by briefly heating to about 45°C, e.g. for 2-5 minutes, and rapidly cooling to the incubation temperature.
  • the treated protoplasts are then cloned and selected for expression of the desired gene, e.g. by expression of the marker gene and conventional blotting techniques. Whole plants are then regenerated from the clones in a conventional manner.
  • the electroporation technique is similar except that electrical current is typically applied to the mixture of naked plasmids and protoplasts, in an electroporation chamber in the absence or presence of polyethylene glycol, Ca 2+ or the like.
  • Typical electroporation includes 1-10 pulses of 40-10,000 DC volts for a duration of 1-2000 ⁇ s with typically 0.2 second intervals between pulses.
  • Alternating current pulses of similar severity can also be used. More typically, a charged capacitor is discharged across the electroporation chamber containing the plasmid protoplast suspension.
  • Another method suitable for transforming dicots involves the use of Agrobacterium. In this method, Agrobacterium containing the plasmid with the desired gene is used to infect plant cells and insert the plasmid into the genome of the cells. The cells expressing the desired gene are then selected and cloned as described above. For example, one method for introduction of a foreign gene into a dicot, e.g., a tuber, root or legume, by means of a plasmid, e.g. an Ri plasmid and an Agrogacterium, e.g. A.
  • a plasmid e.g. an Ri plasmid and an Agrogacterium, e.g. A.
  • rhizogenes or A. tumefaciens is to utilize a small recombinant plasmid suitable for cloning in Escherichia coli, into which a fragment of T-DNA has been spliced. This recombinant plasmid is cleaved open at a site within the T-DNA. A piece of "passenger" DNA is spliced into this opening.
  • the passenger DNA consists of the gene of this invention which is to be incorporated into the plant DNA as well as a selectable marker, e.g., a gene for resistance to an antibiotic.
  • This plasmid is then recloned into a larger plasmid and then introduced into an Agrobacterium strain carrying an unmodified Ri plasmid.
  • a rare double-recombination will sometimes take place resulting in bacteria whose T-DNA harbors an insert: the passenger DNA.
  • Such bacteria are identified and selected by their survival on media containing the antibiotic.
  • These bacteria are used to insert their T-DNA (modified with passenger DNA) into a plant genome. This procedure utilizing A. rhizogenes or A. tumefaciens gives rise to transformed plant cells that can be regenerated into intact healthy, fertile plants.
  • Fig. 1 is a restriction map of pUCP521 and also illustrates a DNA sequence with which a Banll fragment of pUCP521 can be ligated.
  • Fig. 2 is a restriction map of pTP369 of Example 2 containing the gene for protein 13 of phage 22.
  • Fig. 3 is a partial restruction map of pMONP22Ly of Example 3 containing the lysozyme gene of phage P22.
  • Fig. 4 is a partial restriction map of pMONT4Ly of Example 4 containing the lysozyme gene of phage T4.
  • Fig. 5 is restriction maps of pLYS1023, p76-311, p20-211 and pCHLY.
  • Fig. 6 is a restriction map of PMON530.
  • Fig. 7 is a restriction map of pCA2.
  • Fig. 8 is a partial restriction map of pIBI76.
  • Fig. 9 is a partial restriction map of pBI121.
  • Fig. 10 is a partial restriction map of pCAMV2X.
  • Fig. 11 is a graph illustrating the enhancement of essential amino acid content of the lotononis transformants of Example 16.
  • Example 1 A plasmid containing an attacin cDNA sequence, the CaMV 35s promoter and kanamycin/streptomycin/spectinomycin resistance genes was constructed, and is designated herein as pMONAATT.
  • the plasmid pCP521 was obtained from K. Xanthopoulous, and it has a 723 bp insert in the PstI site of pBR322 containing the acidic attacin cDNA sequence without methionine.
  • pCP521 was treated with Banll and PstI to remove the attacin gene.
  • the attacin gene was subcloned into the PstI site of pUC19 by filling in the 3' end of the attacin with T4 DNA polymerase and ligating with T4 DNA ligase.
  • the resulting plasmid was selected for clockwise orientation and designated pUCP521.
  • a restriction map of pUCP521 is seen in Fig. 1. This was digested with Banll. The larger fragments were isolated by gel permeation and ligated with the DNA sequence: 5' CAGATGTAACAATGGACGCGCACGGAGCC 3' 3' TCGAGTCTACATTGTTACCTGCGCGTGCC 5'
  • a 657 bp fragment was rescued by digestion with BglII and EcoRV. This fragment was then ligated between the BglII and SmaI sites of pMON530 and the resulting plasmid was designated pMONATT.
  • a restriction map of unmodified pMON530 is illustrated in Fig. 6.
  • the plasmid pMONAATT was then placed in competent E. coli cells. Into 100 ⁇ l of cells at 10 6 cells/ml, was added 1 ⁇ g of pMONAATT in 10 ⁇ l sterile water and 100 ⁇ l 0.01M CaCl 2 buffer. This mixture was incubated at 4°C for 45 minutes, heat shocked at 42°C for two minutes, placed in 1.5 ml Luria broth at 37°C for two hours and plated on LB-Agar containing 50 ⁇ g/ml kanamycin sulfate. After incubation at 37°C overnight, colonies were selected, grown and screened for kanamycin resistance and the correct attacin gene.
  • Suitable clones in mid to late-log phase were suspended at 10 6 /ml and 0.1 ml was placed on LB-agar plates with a like amount of disarmed vector A. tumefaciens. After about 6 hours at room temperature, the plates were scraped, the cells were serially diluted several times at 1:10 dilution and replated on LB-agar containing 25 ⁇ g/ml chloramphenicol, 50 ⁇ g/ml kanamycin sulfate, and 100 ⁇ g/ml each of streptomycin and spectinomycin.
  • Surviving A. tumefaciens were diluted 1:10 in PBS and N. tabacum leaf discs were briefly dipped in this solution and subsequently plated. After two days of incubation, cefotoxin and kanamycin were added to the media. All cells died, indicating that no transformants were obtained.
  • the pMONAATT clones are digested with EcoRV and HindIII and the attacin fragment is rescued and purified from agarose gel. This fragment is subcloned into pIBI76 (Fig. 8) between the EcoRV and HindIII cleavage sites thereof. The resulting plasmid is then digested with EcoRV and KpnI and the fragment containing the attacin gene is recovered. This fragment is then subcloned into pCA2 (Fig. 12; Science, vol. 236, pp. 1299-1301 (1987)) between the EcoRV and Kpnl sites.
  • This plasmid is then digested with HindIII and PstI to rescue a fragment containing the attacin gene and duplicated CaMV 35s promoters.
  • This fragment is then ligated into pBI121 (Fig. 9; obtained commercially from Clontech Laboratories, Inc.) between the HindIII and PstI sites to obtain the vector illustrated in Fig. 10 and designated pCAMV2X.
  • This vector has the attacin gene under the control of the double CaMV 35s promoters, as well as a ⁇ -glucoronidase ("GUS”) gene.
  • This vector is then cloned in E. coli as described above for pMONATT. The transformed E. coli are conjugated with disarmed vector A.
  • tumefaciens which are subsequently used to infect the tobacco leaf discs as described above. After about 2 weeks, callus tissue develops. Plants are regenerated from the callus and expression of attacin is demonstrable by blotting techniques. The plants are exposed to Pseudomonas syringae but are not infected, in contrast to untransformed plants of the same species identically exposed to the P. syringae under the same conditions.
  • Example 2 A plasmid containing P13 protein of phage P22, the CaMV 35s promoter and kanamycin/streptomycin/spectinomycin resistance genes was constructed, and is designated herein as pMONP22P13.
  • the plasmid pTP369 (Fig. 2) was obtained from A. Poteete.
  • pTP369 was digested with EcoRI and Nael to obtain a fragment of about 1100 bp containing the P13 protein codons. This fragment was ligated into pUC19 between the EcoRI and the HincII cleavage sites thereof to obtain a plasmid designated pTPEN1041.
  • pTPEN1041 was digested with EcoRI and PstI, and a fragment of about 1100 bp was isolated. This was then digested with MaeII and yielded fragments of 437, 348 and 259 bp. The 437 bp fragment ends were filled in using Klenow enzyme and purified from agarose. gel. This was then ligated into pMON530 between the SmaI and LiH sites, and the orientation was checked with Hpal. The resulting plasmid was designated pMONP22P13. The plasmid pMONP22P13 was cloned in E. coli and conjugated with A.
  • tumefaciens which was then cultured with tobacco leaf discs as described in Example 1, but no transformed cells were obtained.
  • the P22 protein gene from the pMONP22P13 clones are then inserted in the HindIII site of pBI121 as described in Example 1, and then used in an A. tumefaciens vector to transform tobacco leaf discs. Callus eventually develops, and plants regenerated therefrom express the phage protein and are resistant to P. syringae.
  • Example 3 A plasmid corresponding to the partial restriction map shown in Fig. 3 was constructed and designated pMONP22Ly.
  • the plasmid pDR116 was obtained from A. Poteete and contained a fragment of about 590 bpp between HindI and TaqI sites [as a BamHI-ClaI insert in a pBR322 derivative containing a BamHI in the Pvul cleavage site.]
  • pDR116 was digested with BamHI and ClaI and the ends of the fragment containing the phage lysozyme gene was filled in using Klenow enzyme and isolated from agarose gel.
  • This approximately 590 bp fragment was ligated into pMON530 at the SmaI/LiH site and the orientation was checked by digestion with EcoRI and DraI.
  • the resulting plasmid was designated pMONP22Ly, cloned in E. coli and conjugated with A. tumefaciens which was then cultured with tobacco leaf discs as described in Example 1. Again, no tobacco transformants resistant to kanamycin were obtained.
  • the P22 lysozyme is then rescued from pMONP22Ly and inserted into pBI121 which is then used to transform E. coli, which in turn is conjugated with A. tumefaciens and used to infect tobacco leaf discs as described in Example 1. Callus eventually develops, and plants regenerated therefrom express the phage lysozyme gene and are resistant to P. syringae.
  • Example 4 A plasmid designated pMONT4Ly was constructed corresponding to the partial restriction map seen in Fig. 4.
  • pDR105 was obtained from A. Poteete and has the lysozyme gene from phage T4 as an approximately 685 bp fragment between the AvaII and HindIII restriction sites.
  • pDR105 was digested with Avail and HindIII, and the lysozyme fragment was filled in with Klenow enzyme and purified from the gel. This fragment was then ligated into pUC19 between the HincII and LiH sites and designated pUCT4Ly. The orientation was checked by digestion with EcoRI, and all 18 clones had obtained clockwise rotation.
  • pUCT4Ly was digested with BamHI, DraI and Avail to avoid fragments of similar length to the BamHI-DraI fragment.
  • the 646 bp BamHI-DraI fragment was ligated into pMON530 between the BglII and SmaI sites adjacent to the LiH region, and the resulting plasmid was designated pMONT4Ly.
  • the proper orientation was confirmed with EcoRI which gave a 353 bp band, and HpaI and EcoRV which gave bands of approximately 8000, 4000 and 604 bp.
  • pMONT4Ly was cloned in E. coli and conjugated with A.
  • Example 5 tumefaciens which was then cultured with tobacco leaf discs as described in Example 1, but again no transformats were obtained. As in Example 1, the leaf disc infection procedure is repeated using the lysozyme gene cut from pMONT4Ly and placed in pBI121. Callus eventually develops, and plants regenerated therefrom express the T4 phage lysozyme and are resistant to P. syringae.
  • the plasmid pLYS1023 (Fig. 5) was digested with PstI and SacI. A 336 bp fragment was isolated and digested with Mnll to obtain the MnlI-SacI 311 bp fragment. This was ligated into pIBI76 between the SacI and SmaI sites. The resulting plasmid was designated p76-311 (Fig. 5). pLYS1023 was then digested with SacI and PstI, and a 252 bp fragment was isolated. This fragment was then digested with DraI and the Sacl-DraI 211 bp fragment was isolated from agarose gel.
  • the 211 bp fragment was then ligated into pIBI20 between the SacI and HincII sites, and the resuting plasmid was designated p20-211.
  • p20-211 was digested with EcoRV and SacI and the fragment was purified from gel. This fragment was then ligated with the HincII-SacI 326 bp fragment from the p76-311 also purified from a gel, to obtain a plasmid designated pCHLy.
  • the lysozyme gene (549 bp) was rescued from pCHLy with BamHI and XhoI and ligated into pMON530 between the BglII and XhoI sites to obtain pMONCHLy.
  • the lysozyme gene is then cut from pMONCHLy and placed in pCAMV2X as described in Example 1. This plasmid is then cloned in E. coli and conjugated with A. tumefaciens which is then cultured with tobacco leaf discs also as described in Example 1. Callus eventually develops, and plants regenerated therefrom express the lysozyme gene and are resistant to P. syringae.
  • Example 6 The lysozyme gene and protein was obtained from Hyalophora-derived plasmid pBR322, provided by Kleanthis Xanthopoulos. The lysozyme gene was removed from the plasmid pBR322 by digestion with the enzyme PstI. The resultant fragment was purified and treated with the Bal31 enzyme to remove the 3 ' poly dG tail. Then the adapter shown as follows:
  • GTTTCATGAAACAGATCTGTCGACAGATCTGTTTCATGAAAC CAAAGTACTTTGTCTAGACAGCTGTCTAGACAAAGTACTTTG was ligated to the fragment after digestion with enzyme XmnI. Then the fragment was digested with SalI and cloned into the plasmid pBR322. The lysozyme gene was rescued by digestion with enzyme Bgl II and inserted into the plant vector pMON237.
  • the plasmid pMON237 is similar to pMON530 except that it has the 19s promoter instead of the 35s, and has only the BglII and EcoRI restriction sites near bp O. The procedure of Example 1 is then followed to place the lysozyme gene in pCAMV2X and to obtain plant transformants.
  • Example 7 The antibacterial protein-producing cecropin gene, obtained in plasmid pBR322 received from Kleanthis Xanthopoulos was first cut with restriction enzymes PstI and HinPII to provide a plasmid fragment pCPFL1. The resulting 260 base pair fragment was purified and treated with T4 DNA polymerase to fill in the HinPII site. The resultant fragment was then treated with T4 DNA ligase and the synthetic adapter C3, which is identified as follows: CTAGCATAAAGATCTGACGTCAGATCTTTATCCTAG GATCGTATTTCTAGACTGCAGTCTAGAAATAGGATC, was joined to the fragment.
  • the new gene fragment was then ligated to pBR322 which had been cleaved with restriction enzymes XmnI and AatII.
  • Clones containing the correct ampicillin sensitive genotype were selected, cut with XmnI and ligated with a synthetic adaptor identified as C5, which has the following nucleotide sequence: CTTTCCATTTCATGGTAGATCTACCATGAAATGGAAAG GAAAGGTAAAGTACCATCTAGATGGTACTTTACCTTTC
  • C5 has the following nucleotide sequence: CTTTCCATTTCATGGTAGATCTACCATGAAATGGAAAG GAAAGGTAAAGTACCATCTAGATGGTACTTTACCTTTC
  • the resultant fragment was retransformed into E. Coli.
  • the cecropin gene is rescued from E. Coli by digestion with BglII and inserted into the plant vector pMON237.
  • the cecropin gene is regenerated without its leader peptide and with an appropriate start methionine at
  • GATCTCCACGGTTGTGGCCATATAATCATCGTGTTTTTCAA effectively blocked 98% of the translation of a virus genome.
  • This procedure was carried out by hybridizing the DNA to the virus in an 8 microliter reaction mixture containing 20 mM Hepes, pH 7.6, 0.1M NaCl and 1mM ETDA. RNA concentration of the virus was 0.5 ⁇ g/ml and the DNA was added in a five-fold molar excess. In general, the reaction mixtures were heated at 70°C for 10 minutes followed by incubation at 45°C for 3 hours.
  • Example 9 In the case of viroids, replication was prevented in the potato spindle tuber viroid (PSTV) by hybridization of synthetic DNA fragments to the PSTV in the central conserved region which appears to be present in all known viroids and is presumed to be important for replication.
  • the synthetic DNA fragments have the oligonucleotide sequence and identification as follows:
  • PSTV RNA PSTV RNA.
  • the sample mixture was heated to 90°C for 5 minutes and then allowed to cool slowly to room temperature. These mixtures were then inoculated onto PSTV sensitive tomato plants and symptoms were allowed to develop. The results are shown in the Table below.
  • PSTV is a full length DNA of PSTV
  • PSTV molecule was blocked.
  • the synthetic DNA transcription blocking for viroids and synthetic DNA translation blocking for viruses are further inserted into the plant vector pCAMV2X and A. tumefaciens to produce tobacco plants which demonstrated expression by Southern blotting.
  • the pCAMV2X of Example 1 is used to transform rice plants (Oryza sativa).
  • An aqueous solution of 100 ⁇ g/ml pCAMV2X is injected with a tuberculin syringe above each tiller node until several drops of the solution comes out of the tiller (about 300 ⁇ l).
  • the plants are injected when the young tillers have 5 leaves, the flag leaf is about one-third to one-half its normal size and they contain a young influorescence of about 2 cm suitable for injection. This corresponds to about 14 days pre-meiosis.
  • the plants are self-pollinated or cross-pollinated with other treated plants and the floral tillers grown to maturity.
  • the seeds from these plants are then surface sterilized, and germinated in glass containers having about 400 ml of Knop nutritive solution supplemented with kanamycin sulfate at 10 ⁇ g/ml. About 10 seeds are positioned in a plastic net over the solution so that they are just in contact therewith. The seeds are maintained in a culture room at about 26°C and receive about 2000 lux for 16 hours per day. Control seeds germinated in the kamaycin nutritive solution are albino after about 10 days. From about 3000 seeds obtained from the injection of 100 plants, about 3-15 remain green after 10 days. Approximately one-third of these plants show expression of the attacin gene by blotting techniques and have enhanced resistance to blast.
  • Example 11 Protoplasts of rice are treated with pCAMV2X of Example 1 to obtain disease-resistant plants. Calli are cultured on a gyrating shaker at 27°C in the dark in a suspension of medium B5 supplemented with 1 mg/1 2,4-dichlorophenoxy-acetic acid and 30 g/1 sucrose, and subcultured twice a week by a 1:3 dilution with fresh medium.
  • Protoplasts are isolated the second or third day following subculturing by sedimenting and incubating in a cell wall digestive solution containing 1% Onozuka Cellulase RS, 0.5% Macerozyme R10, 0.05% Pectolyase Y23, 0.6M mannitol and 5 mM CaCl 2 at pH 5.7. Following incubation at 27°C for three or four hours, protoplasts are separated from the solution by filtering through a series of 100, 50 and 25 ⁇ m stainless steel sieves, and repeated centrifugations with sea water at 700 mOsmol/kg H 2 O.
  • the protoplasts are resuspended at about 2 x 10 6 /ml in medium F, and one ml of protoplast suspension is mixed with 0.4 ml of medium F containing 40% (w/v) polyethylene glycol 1500 and 10-50 ⁇ g pCAMV2X. This mixture is incubated in a laminar flow hood at 22°-24°C for 30 minutes, diluted stepwise over a period of 20 minutes with medium F and protoplasts are collected by sedimentation in sea water and culture medium at 1:1 (v/v). The protoplasts are resuspended at 2-4 x 10 5 protoplasts/ml in medium C8/IV, and placed in 2 ml aliquots in 5 cm 2 dishes maintained at 27°C in the dark.
  • Example 12 Protoplasts of rice are prepared as described in the foregoing Example 11, and suspended at 1 x 10 7 /ml in 0.5 ml PBS. The mixture is heat shocked for five minutes at 45°C and cooled on ice to room temperature. First, the plasmid pCAMV2X of Example 1, and then polyethylene glycol, are added to the mixture at 10-50 ⁇ g/ml and about 8% w/v, respectively. Following incubation for 5 minutes, the mixture is transferred to the chamber of a BIO-RAD electroporator equipped with an ISCO 494 power supply. The power supply is connected to the shock chamber, and set at 2000V and 0.9mA limit.
  • the wattage and current dials are set to 5% and the power supply (capacitor) is discharged.
  • the electroporated protoplasts are then maintained at 20°C for about 10 minutes and diluted with growth medium and agar to form a bead type culture.
  • the protoplasts are cultured at 24°C in the dark for one day and in 500 lux continuous light for 6 days.
  • the protoplasts are then cultured in the same medium containing 50 mg/1 kanamycin sulfate as described in Example 11. Similar results are observed, except the transformation efficiency is higher.
  • Example 13 The following DNA sequence was synthesized on an Applied Biosystems DNA synthesizer: AAGCTTGATCCAACAATGGA AAAATGGATGAAAGAAATCTGGAAAGTGCTTAAAGATATGATCGATAAAATGAAAACTTTCATC CTAGGTTGTTACCTTTTTACCTACTTTCTTTAGACCTTTCACGAATTTCTATACTAGCTATTTTACTTTTGAAAGTAG
  • This DNA sequence is then inserted into the HindIII site of pCAMV2X, and used to transform potatoes using an A. tumefaciens vector.
  • the resulting potatoes express the protein
  • Examples 1-9 and 13 are repeated sequentially with potatoes to obtain a potato with a wide spectrum of microbial resistance to bacteria, fungi, viruses and viroids and enhanced limiting essential amino acid content.
  • potato leaf discs are used instead of tobacco according to the procedure of Example 1.
  • Transformants obtained thereby are then treated with a pCAMV2X vector similar to that of Example 2 except that a different antibiotic resistance marker is present in the plasmid construct for selection of transformants.
  • Transformants expressing the antimicrobial genes of Examples 1 and 2 are then sequentially transformed in the same manner with the vectors of Examples 3-9 and 13, using a different selectable marker in each transformation stage.
  • the resulting potato plants express attacin, lysozyme, cecropin, and the protein of Example 13, and have resistance to a wide spectrum of bacteria, fungi and viruses, as well as an enhanced essential amino acid content.
  • Example 15 The procedure of Example 14 is followed, except that rice is used instead of potatoes, and the electroporation of rice protoplasts described in Example 12 is used instead of the Agrobacterium vector. The resulting rice plants have a similar microbial resistance and enhanced nutritional quality.
  • Example 16 The procedure of Example 14 is followed, except that rice is used instead of potatoes, and the electroporation of rice protoplasts described in Example 12 is used instead of the Agrobacterium vector. The resulting rice plants have a similar microbial resistance and enhanced nutritional quality.
  • Example 16 Example 16
  • the nucleotide sequence and polypeptide sequence of some synthetic polypeptide genes are designated Sp44 and Sp47. These genes were constructed symmetrically so that the correct reading frame is maintained in either direction. Hence, there are two possible polypeptides for each synthetic gene.
  • Single strand DNA sequences were constructed via an automated DNA synthesizer which uses a solid support phosphite synthesis method of the triester method of synthesis.
  • the following synthetic oligonucleotides were constructed: 5' (AAGAAATGGATG)3', 5' (CATCCA)3', 5'(TTTCTT)3', 5'(ACGATC)3', 5'(GATCGT)3', and 5' (CCCGAATTCGGG)3'.
  • the synthetic oligodeoxynucleotides were phosphorylated in the terminal 5'-OH position by the action of T4 polynucleotide kinase.
  • the labeled oligodeoxynucleotides were added to a final volume of 25 ⁇ l with the following molar concentrations: AAGAAATGGATG, TTTCTT, and CATCCA were at 61 ⁇ M each and ACGATC and GATCGT were at 40 ⁇ M each.
  • the sequence containing the EcoRl recognition sequence was at a concentration of 2.4 ⁇ M. This mixture was boiled for 2 minutes and cooled to room temperature for over a period of 3 hours.
  • Ligation buffer was added followed by the enzyme T4 DNA ligase and the resultant mixture incubated at 13°C overnight.
  • the synthetic genes were precipitated with ethanol, redissolved in water and digested wtih EcoRl. After digestion the sample was passed over a Sephadex G-75 column in order to separate the small molecular weight linked fragments from the synthetic genes.
  • the high molecular weight fractions were pooled, precipitated and ligated with EcoRI-digested pBR325.
  • Competent E. coli strain RR1 cells were transformed with the above ligation mixture. Approximately 45 clones which were ampicillin-resistant and chloramphenicol-sensitive were obtained from one ligation.
  • Two recombinant DNA strains designated Sp44 and Sp47 were selected for DNA sequence analysis by the method of Sanger.
  • NUCLEOTIDE SEQUENCE AND AMINO ACID COMPOSITION
  • E. coli cells retaining the plasmids were grown in M9 media supplemented with 5% casamino acids and 1.0 g. per ml thiamine, at 37°C. Ten mis of each culture was placed in 100 mis of the supplemented M9 medium and grown again at 37°. After this time approximately 10 ⁇ Ci each of 3 H lysine and 35 S cysteine were added to the cells and 1 ml was withdrawn hourly and the amount of label incorporated into the polypeptide were determined.
  • the recombinant microbes used contained Sp47 and Sp44 genes on the plasmid pBR325.
  • the control was a bacteria which contained pBR325 alone.

Abstract

La présente invention se rapporte à des agents de transformation végétale ayant un gène hétérologue exprimable pour un agent antimicrobien pour la résistance aux maladies et/ou à une protéine à fort pouvoir de limitation de la teneur en acides aminés essentiels pour une meilleure qualité nutritionnelle. Des monocotylédones, des dicotylédones et des gymnospermes sont génétiquement améliorées pour résister aux maladies, de façon à exprimer un peptide lytique, constitué par exemple de cécropine, d'attacine ou de lysozyme, ou un ARN mic antiviral. La qualité nutritionnelle de plantes dont la culture est destinée à l'alimentation est améliorée par un gène exprimant une protéine contenant 25 à 60 % en poids de méthionine, de lysine, de triptophane, de tréonine et d'isoleucine. Des procédés servant à obtenir de tels agents de transformation, de nouveaux vecteurs d'expression, de nouvelles protéines à haute teneur en acides aminés essentiels et de nouveaux peptides lytiques sont également décrits.
PCT/US1988/003908 1987-11-02 1988-11-02 Plantes ameliorees genetiquement pour resister aux maladies WO1989004371A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP89900103A EP0675960A1 (fr) 1987-11-02 1988-11-02 Plantes ameliorees genetiquement pour resister aux maladies
KR1019890701236A KR890701005A (ko) 1987-11-02 1989-07-03 내병성을 위해 유전적으로 개량시킨 식물

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11594187A 1987-11-02 1987-11-02
US115,941 1987-11-02

Publications (1)

Publication Number Publication Date
WO1989004371A1 true WO1989004371A1 (fr) 1989-05-18

Family

ID=22364287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1988/003908 WO1989004371A1 (fr) 1987-11-02 1988-11-02 Plantes ameliorees genetiquement pour resister aux maladies

Country Status (5)

Country Link
EP (1) EP0675960A1 (fr)
KR (1) KR890701005A (fr)
AU (1) AU2802989A (fr)
CA (1) CA1321157C (fr)
WO (1) WO1989004371A1 (fr)

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0383770A1 (fr) * 1987-07-06 1990-08-29 Univ Louisiana State Inhibition de pathogenes et de neoplasmes eucaryotiques, et stimulation de fibroblastes et de lymphocytes avec des peptides lytiques.
EP0412381A1 (fr) * 1989-08-10 1991-02-13 Bayer Ag Utilisation dans des plantes de constructions du gène de lysozyme pour obtenir une résistance élevée
WO1991002071A2 (fr) * 1989-08-09 1991-02-21 Dekalb Plant Genetics Procedes et compositions de production de plantes monocotyledones fecondes ainsi que de leurs cellules transformees de maniere stable
EP0425616A1 (fr) * 1989-04-11 1991-05-08 Calgene, Inc. Emploi de peptides antimicrobiens derives d'animaux, dans la lutte contre des pathogenes vegetaux
EP0431829A1 (fr) * 1989-11-29 1991-06-12 Agracetus, Inc. Plantes contenant des toxines insecticides
EP0448511A1 (fr) * 1990-03-12 1991-09-25 Ciba-Geigy Ag Combinaisons antipathogènes contenant les peptides lytiques et les enzymes hydrolytiques
WO1991019738A1 (fr) * 1990-06-15 1991-12-26 Hoechst Aktiengesellschaft Polypeptide fongicide et son procede de production
EP0465009A1 (fr) * 1990-06-05 1992-01-08 Pioneer Hi-Bred International, Inc. Peptides antimicrobiens et résistance aux maladies de plantes basé sur ceux-ci
FR2665177A1 (fr) * 1990-07-24 1992-01-31 Sanofi Sa Gene recombinant codant pour une proteine a activite endochitinase et/ou lysozyme.
EP0472987A1 (fr) * 1990-08-10 1992-03-04 ENICHEM S.p.A. Peptides antimicrobiens actifs contre les pathogènes des plantes, leur utilisation et méthodes d'examen collectif appartenant à ces-ci
EP0497366A2 (fr) * 1991-02-01 1992-08-05 ENICHEM S.p.A. Peptides antimicrobiens et leur utilization contre les pathogènes des plantes
EP0525508A2 (fr) * 1991-07-19 1993-02-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Protéine anti-pathogénique de Ustilago maydis, et son utilisation
WO1993003160A1 (fr) * 1991-08-09 1993-02-18 E.I. Du Pont De Nemours And Company Proteines de reserve synthetiques a structure definie contenant des taux programmables d'acides amines essentiels en vue de l'amelioration de la valeur nutritionnelle de plantes
WO1993005645A1 (fr) * 1991-09-19 1993-04-01 Smart Plants International, Inc. Protection des plantes contre des agents pathogenes
WO1993005802A1 (fr) * 1991-09-13 1993-04-01 Magainin Pharmaceuticals Inc. Compositions peptidiques amphiphiles biologiquement actives et utilisations desdites compositions
TR25591A (tr) * 1989-09-05 1993-07-01 Dusar Heinz BIR BANYO DUS SIPERININ PERDESININ TESPITINE MAHSUS DüZEN
EP0552559A2 (fr) * 1991-12-23 1993-07-28 Unilever Plc Plantes transgéniques résistantes aux infections microbiennes
US5235038A (en) * 1991-01-22 1993-08-10 Torry Pines Institute For Molecular Studies Deletion and substitution analogues of melittin peptide
US5294605A (en) * 1990-07-19 1994-03-15 The Scripps Research Institute Amphiphilic peptide compositions and analogues thereof
WO1994010319A1 (fr) * 1992-11-05 1994-05-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Procede permettant d'augmenter la teneur proteique de plantes
EP0616035A2 (fr) * 1992-10-09 1994-09-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Organisme transgénique résistant aux pathogènes
WO1995000653A1 (fr) * 1993-06-21 1995-01-05 Pioneer Hi-Bred International, Inc. Peptides antifongiques de synthese
WO1995016776A1 (fr) * 1993-12-17 1995-06-22 Pioneer Hi-Bred International, Inc. Derives de la tachyplesine presentant une activite inhibitrice vis a vis des champignons pathogenes vegetaux
WO1995018855A2 (fr) * 1994-01-07 1995-07-13 Pioneer Hi-Bred International, Inc. Peptides antimicrobiens de synthese
US5459237A (en) * 1990-02-08 1995-10-17 Magainin Pharmaceuticals Inc. Peptide compositions and uses therefor
EP0684759A1 (fr) * 1992-09-30 1995-12-06 Cornell Research Foundation, Inc. Fruits pomaces transgeniques possedant une resistance au feu bacterien
US5484956A (en) * 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5489520A (en) * 1990-04-17 1996-02-06 Dekalb Genetics Corporation Process of producing fertile transgenic zea mays plants and progeny comprising a gene encoding phosphinothricin acetyl transferase
US5508468A (en) * 1990-01-22 1996-04-16 Dekalb Genetics Corporation Fertile transgenic corn plants
EP0712272A1 (fr) * 1993-07-16 1996-05-22 The Salk Institute For Biological Studies Plantes trangeniques contenant des genes multiples de resistance aux maladies
WO1996038574A1 (fr) * 1995-05-31 1996-12-05 Pioneer Hi-Bred International, Inc. Procedes d'augmentation de l'accumulation d'acides amines essentiels dans des graines
WO1996038563A1 (fr) * 1995-06-02 1996-12-05 Pioneer Hi-Bred International, Inc. DERIVES DE α-HORDOTHIONINE A TENEUR ELEVEE EN METHIONINE
WO1996038562A1 (fr) * 1995-06-02 1996-12-05 Pioneer Hi-Bred International, Inc. Derives d'alpha-hordothionine a teneur elevee en threonine
US5589364A (en) * 1994-07-29 1996-12-31 Magainin Pharmaceuticals Inc. Recombinant production of biologically active peptides and proteins
US5631007A (en) * 1990-03-12 1997-05-20 Ciba-Geigy Corporation Anti-pathogenically effective compositions comprising lytic peptides and hydrolytic enzymes
EP0781347A1 (fr) * 1994-07-22 1997-07-02 Demeter Biotechnologies, Ltd. Produit de recombinaison par fusion de genes de peptides lytiques d'ubiquitine, produits en derivant et leur procede d'obtention
EP0798381A2 (fr) * 1996-03-25 1997-10-01 National Institute Of Agrobiological Resources, Ministry Of Agriculture, Forestry And Fisheries Plantes résistantes aux pathogènes et leur production
WO1998006860A1 (fr) * 1996-08-14 1998-02-19 Novartis Ag Peptide possedant une action inhibitrice a l'encontre de champignons pathogenes de plantes
US5847047A (en) * 1993-06-22 1998-12-08 E. I. Du Pont De Nemours And Company Antimicrobial composition of a polymer and a peptide forming amphiphilic helices of the magainin-type
US5850025A (en) * 1991-09-19 1998-12-15 Sibia Neurosciences, Inc. Protection of plants against plant pathogens
US5856178A (en) * 1993-08-30 1999-01-05 Utah State University DNA cassettes for expression of lytic peptides in mammalian cells and transgenic organisms containing same
EP0896059A2 (fr) * 1990-12-20 1999-02-10 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Méthode de production de plantes résistantes aux pathogènes
WO1999024589A2 (fr) * 1997-11-05 1999-05-20 Mpb Cologne Gmbh Molecular Plant & Protein Biotechnology Proteines et peptides analogues au lysozyme et a action antimicrobienne, leur production et leur utilisation
WO1999040209A1 (fr) * 1998-02-09 1999-08-12 Pioneer Hi-Bred International, Inc. Modification de compositions d'acides amines dans des graines
WO1999055890A1 (fr) * 1998-04-27 1999-11-04 Demegen, Inc. Procede permettant d'augmenter le contenu proteinique des vegetaux
US5990389A (en) * 1993-01-13 1999-11-23 Pioneer Hi-Bred International, Inc. High lysine derivatives of α-hordothionin
EP1004595A2 (fr) * 1989-04-10 2000-05-31 Helix BioMedix, Inc. Peptides lytiques et prolifératifs et leur emploi comme agents pharmaceutiques et phytopharmaceutiques
US6077811A (en) * 1995-06-06 2000-06-20 Mitchell; James P. Vanadium compositions to enhance plant growth and edible fruit yield
EP1174027A1 (fr) * 2000-07-17 2002-01-23 HOM Consultancy B.V. Utilisations de peptides antimicrobiens
EP1389903A2 (fr) * 2001-02-14 2004-02-25 Ventria Bioscience Compositions d'additif alimentaire et methodes associees
USRE39238E1 (en) 1992-10-09 2006-08-15 Max-Planck-Gesellschaft zür Forderung der Wissenschaften e.V. Transgenic pathogen-resistant organism

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8600161A (pt) * 1985-01-18 1986-09-23 Plant Genetic Systems Nv Gene quimerico,vetores de plasmidio hibrido,intermediario,processo para controlar insetos em agricultura ou horticultura,composicao inseticida,processo para transformar celulas de plantas para expressar uma toxina de polipeptideo produzida por bacillus thuringiensis,planta,semente de planta,cultura de celulas e plasmidio
AU611859B2 (en) * 1986-07-25 1991-06-27 Louisiana State University And Agricultural And Mechanical College Method for introduction of disease and pest resistance into plants and novel genes incorporated into plants which code therefor

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BioEssays, Volume 6, issued June 1987, (Cambridge, England), JAYNES et al., "Increasing Bacterial Disease Resistance in Plants Utilizing Antibacterial Genes from Insects", pages 263-270, see pages 267 and 268 in particular. *
Developmental and Comparative Immunology, Volume 9, issued March 1985, (Elmsford, New York, USA), BOMAN et al., "On the Primary Structures of Lysozyme, Cecropins and Attacins from Hyalophora Cecropia", pages 551-558, see pages 552, 553 and 556 in particular. *
Journal of Cellular Biochemistry, Volume Supplement 10C, issued April 1986, (New York, New York, USA), JAYNES et al., "Integration and Expression of Viroid cDNAs in Plant Cells", page 40. *
Journal of Cellular Biochemistry, Volume Supplement 10C, issued April 1986, (New York, New York, USA), LOESCH-FRIES et al., "Cloning of Alfalfa Mosaic Virus Coat Protein Gene and Anti-sense RNA into a Binary Vector and their Expression in Transformed Tobacco Tissue", page 41. *
Nature, Volume 319, issued February 1986, (London, England), FROMM et al., "Stable Transformation of Maize After Gene Transfer by Electroporation", pages 791-793, see pages 791 and 793 in particular. *
PALUKAITIS et al., "A Model to Explain the 'Cross-Protection' Phenomenon Shown by Plant Viruses and Viroids", Volume published 1984, by KOSUGE et al., (New York, New York, USA), pages 420-429, see pages 425-427 in particular. *
Science, Volume 223, issued February 1984, (Washington, D.C., USA), HORSCH et al., "Inheritance of Functional Foreign Genes in Plants", pages 496-498, see page 496 in particular. *
See also references of EP0675960A4 *
Trends in Biotechnology, Volume 4, issued December 1986, (Amsterdam, The Netherlands), JAYNES et al., "Plant Protein Improvement by Genetic Engineering: Use of Synthetic Genes", pages 314-320, see pages 315 and 318 in particular. *

Cited By (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0383770A4 (en) * 1987-07-06 1991-08-14 Louisiana State University And Agricultural And Mechanical College Inhibition of eucaryotic pathogens and neoplasms and stimulation of fibroblasts and lymphocytes with lytic peptides
EP0383770A1 (fr) * 1987-07-06 1990-08-29 Univ Louisiana State Inhibition de pathogenes et de neoplasmes eucaryotiques, et stimulation de fibroblastes et de lymphocytes avec des peptides lytiques.
EP1004595A2 (fr) * 1989-04-10 2000-05-31 Helix BioMedix, Inc. Peptides lytiques et prolifératifs et leur emploi comme agents pharmaceutiques et phytopharmaceutiques
EP1004595A3 (fr) * 1989-04-10 2000-11-02 Helix BioMedix, Inc. Peptides lytiques et prolifératifs et leur emploi comme agents pharmaceutiques et phytopharmaceutiques
EP0425616A1 (fr) * 1989-04-11 1991-05-08 Calgene, Inc. Emploi de peptides antimicrobiens derives d'animaux, dans la lutte contre des pathogenes vegetaux
EP0425616A4 (en) * 1989-04-11 1991-11-27 Calgene, Inc. Use of animal-derived anti-microbial peptides for control of plant pathogens
WO1991002071A3 (fr) * 1989-08-09 1992-05-14 Dekalb Plant Genetics Procedes et compositions de production de plantes monocotyledones fecondes ainsi que de leurs cellules transformees de maniere stable
WO1991002071A2 (fr) * 1989-08-09 1991-02-21 Dekalb Plant Genetics Procedes et compositions de production de plantes monocotyledones fecondes ainsi que de leurs cellules transformees de maniere stable
EP0412381A1 (fr) * 1989-08-10 1991-02-13 Bayer Ag Utilisation dans des plantes de constructions du gène de lysozyme pour obtenir une résistance élevée
US5349122A (en) * 1989-08-10 1994-09-20 Bayer Aktiengesellschaft Use of lysozyme gene structures in plants to increase resistance
US5589626A (en) * 1989-08-10 1996-12-31 Bayer Aktiengesellschaft Use of lysozyme gene structures in plants to increase resistance
TR25591A (tr) * 1989-09-05 1993-07-01 Dusar Heinz BIR BANYO DUS SIPERININ PERDESININ TESPITINE MAHSUS DüZEN
EP0431829A1 (fr) * 1989-11-29 1991-06-12 Agracetus, Inc. Plantes contenant des toxines insecticides
US5508468A (en) * 1990-01-22 1996-04-16 Dekalb Genetics Corporation Fertile transgenic corn plants
US5538880A (en) * 1990-01-22 1996-07-23 Dekalb Genetics Corporation Method for preparing fertile transgenic corn plants
US5538877A (en) * 1990-01-22 1996-07-23 Dekalb Genetics Corporation Method for preparing fertile transgenic corn plants
US5554798A (en) * 1990-01-22 1996-09-10 Dekalb Genetics Corporation Fertile glyphosate-resistant transgenic corn plants
US5484956A (en) * 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5780708A (en) * 1990-01-22 1998-07-14 Dekalb Genetics Corporation Fertile transgenic corn plants
US5459237A (en) * 1990-02-08 1995-10-17 Magainin Pharmaceuticals Inc. Peptide compositions and uses therefor
EP0448511A1 (fr) * 1990-03-12 1991-09-25 Ciba-Geigy Ag Combinaisons antipathogènes contenant les peptides lytiques et les enzymes hydrolytiques
US5631007A (en) * 1990-03-12 1997-05-20 Ciba-Geigy Corporation Anti-pathogenically effective compositions comprising lytic peptides and hydrolytic enzymes
US5348743A (en) * 1990-03-12 1994-09-20 Ciba-Geigy Corporation Anti-pathogenically effective compositions comprising lytic peptides and hydrolytic enzymes
US5489520A (en) * 1990-04-17 1996-02-06 Dekalb Genetics Corporation Process of producing fertile transgenic zea mays plants and progeny comprising a gene encoding phosphinothricin acetyl transferase
US5550318A (en) * 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
AU642257B2 (en) * 1990-06-05 1993-10-14 Pioneer Hi-Bred International, Inc. Natural and synthetic polypeptides with inhibitory activity towards plant pathogenic fungi
EP0465009A1 (fr) * 1990-06-05 1992-01-08 Pioneer Hi-Bred International, Inc. Peptides antimicrobiens et résistance aux maladies de plantes basé sur ceux-ci
US5421839A (en) * 1990-06-15 1995-06-06 Hoechst Aktiengesellschaft Antifungal polypeptide and process for its production
WO1991019738A1 (fr) * 1990-06-15 1991-12-26 Hoechst Aktiengesellschaft Polypeptide fongicide et son procede de production
US5589624A (en) * 1990-06-15 1996-12-31 Hoechst Aktiengesellschaft Antifungal polypeptide and process for its production
US5824874A (en) * 1990-06-15 1998-10-20 Hoechst Aktiengesellschaft Antifungal polypeptide and process for its production
US5294605A (en) * 1990-07-19 1994-03-15 The Scripps Research Institute Amphiphilic peptide compositions and analogues thereof
FR2665177A1 (fr) * 1990-07-24 1992-01-31 Sanofi Sa Gene recombinant codant pour une proteine a activite endochitinase et/ou lysozyme.
EP0472987A1 (fr) * 1990-08-10 1992-03-04 ENICHEM S.p.A. Peptides antimicrobiens actifs contre les pathogènes des plantes, leur utilisation et méthodes d'examen collectif appartenant à ces-ci
EP0896059A2 (fr) * 1990-12-20 1999-02-10 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Méthode de production de plantes résistantes aux pathogènes
EP0896059A3 (fr) * 1990-12-20 1999-07-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Méthode de production de plantes résistantes aux pathogènes
US5235038A (en) * 1991-01-22 1993-08-10 Torry Pines Institute For Molecular Studies Deletion and substitution analogues of melittin peptide
EP0497366A3 (fr) * 1991-02-01 1994-02-09 Donegani Guido Ist
EP0919566A2 (fr) * 1991-02-01 1999-06-02 ENICHEM S.p.A. Peptides antimicrobiens et leur utilization contre les pathogènes des plantes
EP0919566A3 (fr) * 1991-02-01 1999-12-01 ENICHEM S.p.A. Peptides antimicrobiens et leur utilization contre les pathogènes des plantes
EP0497366A2 (fr) * 1991-02-01 1992-08-05 ENICHEM S.p.A. Peptides antimicrobiens et leur utilization contre les pathogènes des plantes
EP0525508A3 (en) * 1991-07-19 1993-08-18 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Anti-palnogenic protein of ustilago maydis and use thereof
EP0525508A2 (fr) * 1991-07-19 1993-02-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Protéine anti-pathogénique de Ustilago maydis, et son utilisation
US5559223A (en) * 1991-08-09 1996-09-24 E. I. Dupont De Nemours And Company Synthetic storage proteins with defined structure containing programmable levels of essential amino acids for improvement of the nutritional value of plants
WO1993003160A1 (fr) * 1991-08-09 1993-02-18 E.I. Du Pont De Nemours And Company Proteines de reserve synthetiques a structure definie contenant des taux programmables d'acides amines essentiels en vue de l'amelioration de la valeur nutritionnelle de plantes
US5470950A (en) * 1991-09-13 1995-11-28 Magainin Pharmaceuticals Inc. Biologically active amphiphilic peptide compositions and uses therefor
WO1993005802A1 (fr) * 1991-09-13 1993-04-01 Magainin Pharmaceuticals Inc. Compositions peptidiques amphiphiles biologiquement actives et utilisations desdites compositions
US5422108A (en) * 1991-09-19 1995-06-06 Smart Plants International Inc. Protection of plants against plant pathogens
WO1993005645A1 (fr) * 1991-09-19 1993-04-01 Smart Plants International, Inc. Protection des plantes contre des agents pathogenes
US5850025A (en) * 1991-09-19 1998-12-15 Sibia Neurosciences, Inc. Protection of plants against plant pathogens
EP0552559A3 (fr) * 1991-12-23 1994-02-09 Unilever Plc
EP0552559A2 (fr) * 1991-12-23 1993-07-28 Unilever Plc Plantes transgéniques résistantes aux infections microbiennes
EP0684759A4 (fr) * 1992-09-30 1996-05-08 Cornell Res Foundation Inc Fruits pomaces transgeniques possedant une resistance au feu bacterien.
US5824861A (en) * 1992-09-30 1998-10-20 Cornell Research Foundation, Inc. Transgenic pomaceous fruit with fire blight resistance
US6100453A (en) * 1992-09-30 2000-08-08 Cornell Research Foundation, Inc. Transgenic pomaceous fruit with fire blight resistance
EP0684759A1 (fr) * 1992-09-30 1995-12-06 Cornell Research Foundation, Inc. Fruits pomaces transgeniques possedant une resistance au feu bacterien
EP0616035A2 (fr) * 1992-10-09 1994-09-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Organisme transgénique résistant aux pathogènes
EP0616035A3 (fr) * 1992-10-09 1995-02-15 Max Planck Gesellschaft Organisme transgénique résistant aux pathogènes.
US5689045A (en) * 1992-10-09 1997-11-18 Max-Planck Gesellschaft Zur Forderung Der Wissenschaften Transgenic pathogen-resistant plant
USRE39238E1 (en) 1992-10-09 2006-08-15 Max-Planck-Gesellschaft zür Forderung der Wissenschaften e.V. Transgenic pathogen-resistant organism
US6271438B1 (en) 1992-10-09 2001-08-07 LOGEMANN JüRGEN Transgenic pathogen-resistant plant
WO1994010319A1 (fr) * 1992-11-05 1994-05-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Procede permettant d'augmenter la teneur proteique de plantes
US5990389A (en) * 1993-01-13 1999-11-23 Pioneer Hi-Bred International, Inc. High lysine derivatives of α-hordothionin
USRE39562E1 (en) * 1993-01-13 2007-04-10 Pioneer Hi-Bred International, Inc. High lysine derivatives of α-hordothionin
US5464944A (en) * 1993-06-21 1995-11-07 Pioneer Hi-Bred International, Inc. Synthetic antifungal peptides
WO1995000653A1 (fr) * 1993-06-21 1995-01-05 Pioneer Hi-Bred International, Inc. Peptides antifongiques de synthese
US5847047A (en) * 1993-06-22 1998-12-08 E. I. Du Pont De Nemours And Company Antimicrobial composition of a polymer and a peptide forming amphiphilic helices of the magainin-type
EP0712272A1 (fr) * 1993-07-16 1996-05-22 The Salk Institute For Biological Studies Plantes trangeniques contenant des genes multiples de resistance aux maladies
EP0712272A4 (fr) * 1993-07-16 1997-08-20 Salk Inst For Biological Studi Plantes trangeniques contenant des genes multiples de resistance aux maladies
US5856178A (en) * 1993-08-30 1999-01-05 Utah State University DNA cassettes for expression of lytic peptides in mammalian cells and transgenic organisms containing same
US5580852A (en) * 1993-12-17 1996-12-03 Pioneer Hi-Bred International, Inc. Derivatives of tachyplesin having inhibitory activity towards plant pathogenic fungi
WO1995016776A1 (fr) * 1993-12-17 1995-06-22 Pioneer Hi-Bred International, Inc. Derives de la tachyplesine presentant une activite inhibitrice vis a vis des champignons pathogenes vegetaux
WO1995018855A2 (fr) * 1994-01-07 1995-07-13 Pioneer Hi-Bred International, Inc. Peptides antimicrobiens de synthese
WO1995018855A3 (fr) * 1994-01-07 1995-10-19 Pioneer Hi Bred Int Peptides antimicrobiens de synthese
EP0781347A1 (fr) * 1994-07-22 1997-07-02 Demeter Biotechnologies, Ltd. Produit de recombinaison par fusion de genes de peptides lytiques d'ubiquitine, produits en derivant et leur procede d'obtention
EP0781347A4 (fr) * 1994-07-22 2000-03-22 Demeter Biotech Ltd Produit de recombinaison par fusion de genes de peptides lytiques d'ubiquitine, produits en derivant et leur procede d'obtention
US5589364A (en) * 1994-07-29 1996-12-31 Magainin Pharmaceuticals Inc. Recombinant production of biologically active peptides and proteins
WO1996038574A1 (fr) * 1995-05-31 1996-12-05 Pioneer Hi-Bred International, Inc. Procedes d'augmentation de l'accumulation d'acides amines essentiels dans des graines
WO1996038562A1 (fr) * 1995-06-02 1996-12-05 Pioneer Hi-Bred International, Inc. Derives d'alpha-hordothionine a teneur elevee en threonine
US5885801A (en) * 1995-06-02 1999-03-23 Pioneer Hi-Bred International, Inc. High threonine derivatives of α-hordothionin
WO1996038563A1 (fr) * 1995-06-02 1996-12-05 Pioneer Hi-Bred International, Inc. DERIVES DE α-HORDOTHIONINE A TENEUR ELEVEE EN METHIONINE
US6077811A (en) * 1995-06-06 2000-06-20 Mitchell; James P. Vanadium compositions to enhance plant growth and edible fruit yield
EP0798381A3 (fr) * 1996-03-25 1998-06-17 National Institute Of Agrobiological Resources, Ministry Of Agriculture, Forestry And Fisheries Plantes résistantes aux pathogènes et leur production
US6750381B2 (en) 1996-03-25 2004-06-15 National Institute Of Agrobiological Sciences Pathogen-resistant plants transformed with a DNA encoding sarcotoxin 1A linked to a signal peptide and a method for production thereof
EP0798381A2 (fr) * 1996-03-25 1997-10-01 National Institute Of Agrobiological Resources, Ministry Of Agriculture, Forestry And Fisheries Plantes résistantes aux pathogènes et leur production
WO1998006860A1 (fr) * 1996-08-14 1998-02-19 Novartis Ag Peptide possedant une action inhibitrice a l'encontre de champignons pathogenes de plantes
WO1999024589A3 (fr) * 1997-11-05 1999-11-04 Mpb Cologne Gmbh Molecular Pla Proteines et peptides analogues au lysozyme et a action antimicrobienne, leur production et leur utilisation
WO1999024589A2 (fr) * 1997-11-05 1999-05-20 Mpb Cologne Gmbh Molecular Plant & Protein Biotechnology Proteines et peptides analogues au lysozyme et a action antimicrobienne, leur production et leur utilisation
WO1999040209A1 (fr) * 1998-02-09 1999-08-12 Pioneer Hi-Bred International, Inc. Modification de compositions d'acides amines dans des graines
WO1999055890A1 (fr) * 1998-04-27 1999-11-04 Demegen, Inc. Procede permettant d'augmenter le contenu proteinique des vegetaux
EP1174027A1 (fr) * 2000-07-17 2002-01-23 HOM Consultancy B.V. Utilisations de peptides antimicrobiens
EP1389903A2 (fr) * 2001-02-14 2004-02-25 Ventria Bioscience Compositions d'additif alimentaire et methodes associees
EP1389903A4 (fr) * 2001-02-14 2006-09-06 Ventria Bioscience Compositions d'additif alimentaire et methodes associees

Also Published As

Publication number Publication date
EP0675960A1 (fr) 1995-10-11
EP0675960A4 (fr) 1995-04-13
CA1321157C (fr) 1993-08-10
AU2802989A (en) 1989-06-01
KR890701005A (ko) 1989-12-19

Similar Documents

Publication Publication Date Title
US5811654A (en) Plants genetically enhanced for nutritional quality
CA1321157C (fr) Plantes genetiquement ameliorees, a plus grande resistance aux maladies
RU2140985C1 (ru) Выделенная и очищенная молекула нуклеиновой кислоты, не встречающаяся в природе молекула нуклеиновой кислоты и способ придания растению устойчивости к вирусу табачной мозаики (варианты)
EP0455665B1 (fr) Production de semences hybrides
EP0392225A2 (fr) Plantes transgéniques résistantes aux maladies
JPH04229182A (ja) 新規シグナル配列
CA2226889C (fr) Sequence de regulation d'expression utilisee dans l'expression generale et effective de genes dans les vegetaux
AU665173B2 (en) Endogenously sweetened transgenic plant products
US7081568B2 (en) Transgenic plants expressing temporin peptides
US6043410A (en) Strawberry fruit promoters for gene expression
Zakharchenko et al. Enhanced resistance to phytopathogenic bacteria in transgenic tobacco plants with synthetic gene of antimicrobial peptide cecropin P1
US7557264B2 (en) Gossypium hirsutum tissue-specific promoters and their use
CA2293992A1 (fr) Production d'un poinsettia trangenique
AU618011B2 (en) Preparation of novel protein sweeteners-monellin type
AU772964C (en) Transgenic plants that are resistant to a broad spectrum of pathogens
EP1203086B1 (fr) Element similaire de mite et element d'activation de transcription
JPH07213185A (ja) 含硫アミノ酸含量の改良植物および改良方法
Kuehnle et al. Genetic transformation in Anthurium
JPH10215884A (ja) 酸味抑制剤、植物用プラスミド、形質転換細胞及び形質転換植物、並びにクルクリン製造方法
WO1988010303A1 (fr) Preparation de nouveaux edulcorants proteiniques
AU705682C (en) An expression control sequence for general and effective expression of genes in plants
KR20050028129A (ko) 식물체에서 발현된 소-유래 락토페리신
MXPA99009123A (en) Strawberry fruit promoters for gene expression
KR20050028128A (ko) 식물체에서 발현된 인간-유래 락토페리신
KR20050028330A (ko) 식물체에서 발현된 돼지-유래 락토페리신

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU FI JP KR NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989900103

Country of ref document: EP

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 1989900103

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1989900103

Country of ref document: EP